Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03952403
Recruitment Status : Not yet recruiting
First Posted : May 16, 2019
Last Update Posted : May 20, 2019
Sponsor:
Information provided by (Responsible Party):
Shanghai Henlius Biotech

Brief Summary:
This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed). Part 2 is a randomized, open-label study, which will evaluate the safety and efficacy of HLX10 in combination with carboplatin+pemetrexed with or without HLX04(biosimilar of avastin) compared with treatment with carboplatin+pemetrexed in 1st line Stage IV non-squamous NSCLC. Participants will be randomized in a 1:1:1 ratio to Arm A (HLX10+HLX04+Carboplatin+Pemetrexed), Arm B (HLX10+Carboplatin+Pemetrexed), or Arm C (Carboplatin+Pemetrexed).

Condition or disease Intervention/treatment Phase
Carcinoma Non-Small-Cell Lung Drug: HLX10, an engineered anti-PD-1 antibody Drug: HLX04, a bevacizumab biosimilar Drug: Carboplatin Drug: Pemetrexed Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 636 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Estimated Study Start Date : July 30, 2019
Estimated Primary Completion Date : August 30, 2021
Estimated Study Completion Date : March 2, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1-Cohort 1 (HLX10+HLX04+Carboplatin+Pemetrexed)
Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Drug: HLX10, an engineered anti-PD-1 antibody
HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.

Drug: HLX04, a bevacizumab biosimilar
HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.

Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.

Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.

Experimental: Part 2-Arm A (HLX10+HLX04+Carboplatin+Pemetrexed)
Participants will receive IV infusion of HLX10 and HLX04 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and HLX04 and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Drug: HLX10, an engineered anti-PD-1 antibody
HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.

Drug: HLX04, a bevacizumab biosimilar
HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.

Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.

Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.

Experimental: Part 2-Arm B (HLX10+Carboplatin+Pemetrexed)
Participants will receive IV infusion of HLX10 on Day 1 of each 21-day cycle followed by IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion of HLX10 until loss of clinical benefit and Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Drug: HLX10, an engineered anti-PD-1 antibody
HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.

Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.

Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.

Active Comparator: Part 2-Arm C (Carboplatin+Pemetrexed)
Participants will receive IV infusion of Carboplatin and Pemetrexed on Day 1 of each 21-day cycle for 4 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants will receive IV infusion Pemetrexed until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Drug: Carboplatin
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.

Drug: Pemetrexed
Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: baseline to 21 days ]
  2. Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 24months) ]

Secondary Outcome Measures :
  1. Part 1 and 2-Incidence rates of AEs and SAEs [ Time Frame: Baseline up to approximately 27months ]
  2. Part 1 and 2-Overall Survival (OS) [ Time Frame: Baseline until death (up to approximately 36 months) ]
  3. Part 1-PFS (assessed by the investigator according to RECIST v1.1) [ Time Frame: Baseline until disease progression or death, whichever occurs first (up to approximately 36months) ]
  4. Part 1 and 2-Objective response rate (ORR, assessed by IRRC and investigator according to RECIST v1.1 criteria) [ Time Frame: Baseline up to approximately 24 months ]
  5. Part 1 and 2-Duration of response (DOR, assessed by IRRC and investigator according to RECIST v1.1 criteria) [ Time Frame: Baseline up to approximately 36 months ]
  6. Part 1 and 2-Pharmacokinetics (PK): serum HLX10 concentration [ Time Frame: Baseline up to approximately 25 months ]
  7. Part 1 and 2-Immunogenicity evaluation: positive anti-drug antibody (ADA) rate [ Time Frame: Baseline up to approximately 25 months ]
  8. Part 1 and 2-PD-L1 expression level [ Time Frame: Baseline ]
  9. Part 1 and 2-Microsatellite instability(MSI) [ Time Frame: Baseline ]
  10. Part 1 and 2-Tumor mutation burden(TMB) [ Time Frame: Baseline ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed, Stage IV non-squamous NSCLC
  2. Participants with no EGFR, ALK and ROS1 mutation.
  3. Participants with no prior treatment for Stage IV non-squamous NSCLC
  4. Measurable disease as defined by RECIST v1.1
  5. Eastern Cooperative Oncology Group performance status 0 or 1
  6. Adequate hematologic and end organ function

Exclusion Criteria:

  1. Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  2. Active central nervous system metastases
  3. Prior treatment with cluster of differentiation immune checkpoint blockade therapies or Bevacizumab
  4. Has received a surgical operation within 4 weeks from the initial drug administration
  5. Active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
  6. Currently having or have had interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity
  7. Any active infection requiring systemic anti-infective therapy within 14 days prior to study drug administration
  8. Uncontrollable active infection(s)
  9. History of immunodeficiency, including HIV antibody positive
  10. active hepatitis B; or hepatitis C virus infections
  11. Has bleeding tendency
  12. History of severe cardiovascular diseases
  13. Known gastrointestinal diseases as follows, Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or > moderate esophageal varices
  14. Pregnant or breastfeeding female

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03952403


Contacts
Layout table for location contacts
Contact: Jack Shan +86 158 1071 2378 yong_shan@henlius.com
Contact: Peipei Zai +86 155 2206 7076 peipei_zhai@henlius.com

Sponsors and Collaborators
Shanghai Henlius Biotech
Investigators
Layout table for investigator information
Principal Investigator: Yankai Shi, professor Cancer Hospital Chinese Academy of Medical Sciences (CAMS)

Layout table for additonal information
Responsible Party: Shanghai Henlius Biotech
ClinicalTrials.gov Identifier: NCT03952403     History of Changes
Other Study ID Numbers: HLX10-002-NSCLC301
First Posted: May 16, 2019    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Bevacizumab
Carboplatin
Pemetrexed
Antibodies
Immunoglobulins
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors